Welcome to our dedicated page for Telix Pharmaceuticals SEC filings (Ticker: TLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Telix Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Telix Pharmaceuticals's regulatory disclosures and financial reporting.
Telix Pharmaceuticals Limited submitted a Form 6-K to update U.S. investors on a clinical development milestone first disclosed in Australia. On December 8, 2025, the company filed an announcement with the Australian Securities Exchange titled “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” and this announcement is attached to the Form 6-K as Exhibit 99.1. The filing itself mainly serves as a cross-border notice and does not include additional financial results or transaction details beyond referencing the attached announcement.
Telix Pharmaceuticals Limited reported that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through status for Gozellix. The company filed an announcement with the Australian Securities Exchange titled "CMS Grants Transitional Pass-Through Status for Gozellix," and the related press release is attached as Exhibit 99.1 to the report. No financial metrics, guidance, or additional transaction details are included in the filing.
Telix Pharmaceuticals Limited submitted a Form 6-K summarizing two announcements it filed with the Australian Securities Exchange in August 2025. One announcement, dated August 28, 2025, provides a regulatory update on its TLX250-CDx program. The other, dated August 5, 2025, presents historical financials in U.S. dollars and unaudited operating expenses for the first half of 2025. Both announcements are attached as exhibits to the Form 6-K.
Telix Pharmaceuticals Limited (TLX) has furnished a Form 6-K announcing its Q2 2025 top-line result. The company disclosed US$240 million in quarterly revenue, a 63% year-over-year increase, via an accompanying ASX press release (Exhibit 99.1). No additional income-statement, cash-flow or forward-guidance metrics are included in this filing. The document serves primarily to place the Australian announcement into the U.S. market via the SEC.
While the strong revenue growth signals continuing commercial traction for Telix’s radiopharmaceutical portfolio, investors will need to consult the full press release or upcoming results for margin, profit and outlook details. The filing was signed by Company Secretary Genevieve Ryan on 22 July 2025.